Best of ASCO - 2014 Annual Meeting

 

Welcome

Circulating Biomarkers

Developmental Therapeutics and Tumor Biology (Nonimmuno)

2019 ASCO Annual Meeting

Sort by: title abstract no. first author
ABSTRACT TITLEFIRST AUTHORABSTRACT NO.
REG4 as a novel biomarker of lung adenocarcinoma with mutated KRAS and TTF-1 low expression.

Hui Yu

e14541

A highly efficient, low-cost, novel multicomponent nanosystem for rapid enumeration of circulating tumor cells.

Jayant Khandare

e14516

A prospective study tracking longitudinal changes in genome-wide cell-free DNA (cfDNA) methylation to identify early nonresponders to cancer treatment.

Andrew A. Davis

3042

Analysis of AKR1B10 levels among various groups of breast cancer patients.

Krishna A. Rao

e14548

Analysis of circulating tumor DNA to monitor metastatic breast cancer patients treated with first-line chemotherapy (CAMELLIA study).

Zongbi Yi

e14568

Analytical validation of a tumor-agnostic integrated multianalyte circulating tumor DNA (ctDNA) assay in early-stage cancer.

Anna Hartwig

3057

Assessing the impact of clonal hematopoiesis in disease monitoring using targeted cell-free DNA (cfDNA) sequencing technology.

Stephanie J. Yaung

e14530

Association of forkhead box protein O1 and paired box gene 3 overexpression with prognosis in patients with cervical cancer.

Hanbyoul Cho

e14519

Associations between baseline serum biomarker levels and cachexia/precachexia in pretreated non-small cell lung cancer (NSCLC) patients.

Gabriela C. Lobato

3054

Associations of insulin-like growth factor binding proteins and adiponectin with disease progression and mortality in metastatic colorectal cancer: Results from CALGB/SWOG 80405 (Alliance).

Brendan John Guercio

3035

Baseline cfDNA characteristics and evolution of cfDNA profile during treatment with selective FGFR inhibitor TAS-120.

Tyler J. Moss

3056

Bone metastasis unique plasma exosomal microRNA signature in non-small cell lung cancer.

Can Pi

e14534

Can the enumeration of circulating tumor cells (CTCs) and the characterization of circulating tumor DNA (ctDNA) provide insight into organ tropism in metastatic breast cancer (MBC)?

Lorenzo Gerratana

3038

Cell-free DNA in uveal melanoma: Results from the first-in-human trial of mivebresib (ABBV-075).

Sapna Pradyuman Patel

e14526

Cell-free DNA methylation markers for noninvasive early detection of nasopharyngeal carcinoma.

Dhruvajyoti Roy

e14537

Cell-free methylated DNA (cfMeDNA) immunoprecipitation and high throughput sequencing technology (cfMeDIP-seq) in patients with clear cell renal cell carcinoma (ccRCC).

Pier Nuzzo

3052

cfDNA analysis to reveal association of genomic features with chemotherapy response and survival in patients with pulmonary large-cell neuroendocrine carcinoma.

Minglei Zhuo

e14555

Changes in DNA hydroxymethylation for the detection of multiple cancers in plasma cell-free DNA.

Anna Bergamaschi

3058

Circulating androgen receptor (AR) gene amplification and resistance to 177Lu-PSMA-617 in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Results of a phase II clinical trial.

Ugo De Giorgi

3020

Circulating bacterial DNA as a tool towards noninvasive biomarkers for colorectal adenocarcinoma and adenoma.

Ke-Feng Ding

3045

Circulating cell-free tumor DNA chromosomal instability and circulating tumor cells as tools to predict microvascular invasion of hepatocellular carcinoma.

Jin Wang

e14524

Circulating tumor DNA (ctDNA) mutation and epigenomic patterns in early-stage lung cancer patients and its utility in identifying patients at high risk for early recurrence.

Jong Ho Cho

e14557

Circulating tumor DNA molecular profiling in rare cancer patients from the MASTER KEY Project.

Hitomi Sumiyoshi Okuma

e14532

Circulating-free DNA analysis from long-term surviving metastatic colorectal cancer patients undergoing surgery for resectable disease.

Michele Ghidini

e14545

Clinical significance of circulating tumor cells identified by cell-surface vimentin in pancreatic cancer.

Tao Wei

e14562

Comprehensive genomic profiling of circulating cell-free DNA (cfDNA) distinguishes focal amplification (amp) from aneuploidy among MET amps in diverse advanced cancer types.

Yuichi Kumaki

3046

CTC enumeration and characterization as a pharmacodynamic marker in the phase I clinical study of APX3330, an APE1/Ref-1 inhibitor, in patients with advanced solid tumors.

Lincy Chu

e14531

CTC versus biopsy tissue sequencing: A concordance analysis of genomic copy number profile from mCRPC patients (pts).

Howard I. Scher

3050

Detection of circulating cancer stem cells (cCSCs) as a predictive biomarker for breast cancer relapse or metastasis.

Monika Pizon

e14559

Detection of low abundant mutants from circulating tumor DNA of plasma, pleural effusion, and cerebrospinal fluid of lung cancer patients using a novel mutant-capture enrichment approach.

Rui Lin

e14520

Development and analytical validation of a 523-gene clinical assay for cell-free DNA.

Robin Harrington

3039

Dynamic change of PD-L1 expression on circulating tumor cells in advanced breast cancer undergoing PD-1 blockade therapy.

Tao Wang

e14558

Dynamic monitoring of circulating tumor DNA next-generation gene sequencing as a predictive biomarker of response and progression-free survival after pembrolizumab monotherapy in patients with advanced NSCLC.

Charu Aggarwal

3040

Efficacy of tyrosine kinase inhibitors (TKIs) based on the ALK resistance mutations on amplicon-based liquid biopsy in ALK positive non-small cell lung cancer (NSCLC) patients (pts).

Laura Mezquita

3055

EGF (epidermal growth factor) receptor expression in blood: Prognostic biomarker in overall survival (OS) of patients with non-metastatic triple negative (TN) breast carcinoma.

Rogerio Agenor De Araujo

e14518

Elevated plasma cell-free DNA copy number variations to predict survival for cancer patient with spinal metastasis.

Su Chen

e14522

Epigenomic profiling of plasma cell-free DNA (cfDNA) to predict bladder cancer recurrence after radical cystectomy.

Yi-Tsung Lu

e14525

Follow-up evaluation of outliers with elevated spermine-spermidine acetyltransferase-1 activity.

Andrew W. Maksymiuk

e14536

Functional cell profiling (FCP) of ~100,000 CTCs from multiple cancer types identifies morphologically distinguishable CTC subtypes within and between cancer types.

Gordon Vansant

e14553

Genetic mutation analysis of plasma circulating tumor DNA by ultra-deep sequencing in breast benign lesions and cancers.

Qian Wu

e14572

Genome-wide cell-free DNA (cfDNA) methylation signatures and effect on tissue of origin (TOO) performance.

Minetta C. Liu

3049

Genome-wide cell-free DNA fragmentation profiling for early cancer detection.

Alessandro Leal

3018

Identification and validation of a serum microRNA panel for detection of early-stage breast cancer.

Ruiyang Zou

3051

Identify driver mutants in lung cancer by supernatants of pleural effusion and monitor resistance to targeted therapy.

Yuehong Wang

e14554

Imaging features of genomic instability in circulating tumor cells (CTCs) from metastatic triple-negative breast cancer (metTNBC) patients (pts) who received PIKTOR.

Priscilla Ontiveros

e14527

Inflammatory biomarkers as pronostic factors of mortality in critical ILL oncology patients at ICU.

Carlos Aliaga Macha

e14535

Integrin β5 in plasma-derived exosomal protein predicting liver-specific metastasis in advanced gastric cancer patients.

Qian Li

e14521

Longitudinal monitoring of cell-free DNA to predict for transarterial chemo-embolization failure in hepatocellular carcinoma.

Joanne Evans

e14544

Low-coverage whole genome sequencing of FFPE-derived-DNA and extracellular vesicle-associated DNA in patients with metastatic cancer.

Bella Hai Nguyen

e14523

Mastocheck: Notable plasma protein biomarker for diagnosis of breast cancer in the real clinical practice by using multiple reaction monitoring-based mass spectrometry.

Yumi Kim

3044

MET amplification and exon 14 skipping in treatment naïve patients in lung cancer.

Yaqian Han

e14543

Modeling of pharmacodynamic (PD) biomarkers (BM) related to CDK4/6 inhibition and exploratory BM-response (progression free survival [PFS]) analyses in patients with advanced breast cancer.

Yanke Yu

e14528

Multimodality liquid biopsy for early monitoring and outcome prediction in first-line metastatic HER2-negative breast cancer: Final results of the prospective cohort from the French Breast Cancer InterGroup Unicancer (UCBG)— COMET study.

Jean-Yves Pierga

3019

NMR-metabolite-resonance signature to predict HR+ breast cancer patient response to CDK4/6 inhibitors.

Bo Zhang

3043

PDL1 landscape in checkpoint inhibitor ineligible patients by IHC and cfRNA.

Shumei Kato

e14570

Polymorphisms in the dopamine (DA) signaling to predict outcome in patients (pts) with metastatic colorectal cancer (mCRC): Data from TRIBE, MAVERICC, and FIRE-3 phase III trials.

Francesca Battaglin

3048

Precise prediction of the radiation pneumonitis with RPI: An explorative preliminary mathematical model using genotype information.

Lehui Du

e14569

Predictive and prognostic values of circulating tumor DNA (ctDNA) clearance in osimertinib treated advanced non-small cell lung cancer cohort.

Yong Song

3036

Progastrin, a novel ubiquitous cancer blood biomarker for early detection and monitoring.

Benoit You

3037

Real-world application of liquid biopsy in gastrointestinal tumors: Experience from a comprehensive cancer center.

Enrique Sanz-Garcia

e14546

RNA-based biomarker signatures in plasma as an independent predictor of outcome to chemotherapy in lung, colon, and breast cancers: Correlation of relative PD-L1 expression with immunotherapy outcomes.

Luis E. Raez

e14567

Systemic immune-inflammation index to predict prognosis of elderly patients with newly diagnosed solid tumors.

Chan Li

e14517

The utility of circulating tumor DNA analysis to identify BRAF mutations in malignant melanoma.

Eric Kirby

e14539

Tracking circulating cell-free tumor DNA in gastric cancer to detect early disease recurrence.

Jian Yang

e14571

Tracking endocrine resistance in estrogen-receptor positive breast cancer in ctDNA.

Magdalena Meissner

e14550

Training and validation study for sequential monitoring of CAMLs in circulation to predict ongoing progression in lung cancer patients undergoing definitive radiotherapy.

Daniel Adams

3053

Tumor specific DNA in bronchial lavage as a new diagnostic tool in lung cancer.

Caroline Brenner Thomsen

3047

Whole-genome cell-free DNA (cfDNA) changes as a dynamic blood-based biomarker for early response assessment of advanced tumors.

Andrew A. Davis

3041

Zero delay plasma vs. Streck cfDNA tubes: Does immediately centrifuging blood at the point of draw improve cell-free DNA signal-to-noise?

Greg Sommer

e14529